Biotech hits the brakes on their PhI­II piv­otal for a lead an­tibi­ot­ic as in­ves­ti­ga­tors track a high rate of kid­ney in­juries

The Swiss biotech Polyphor is back with a fresh cau­tion­ary tale about the an­tibi­otics sec­tor.

Just days away from its first an­niver­sary of an IPO $POLN that raised $165 mil­lion, the de­vel­op­er said late last week that it is halt­ing en­roll­ment in its piv­otal tri­al of its an­tibi­ot­ic murepavadin for noso­co­mi­al pneu­mo­nia af­ter in­ves­ti­ga­tors tracked high rates of acute kid­ney in­jury in their Phase III tri­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.